NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai. She spoke about research she and colleagues recently presented at the American Epilepsy Society Annual Meeting on poststroke epilepsy, the ongoing clinical efforts to manage seizures occurring after stroke, what studies still need to explore, and more.Looking for more epilepsy discussion? Check out the NeurologyLive® epilepsy clinical focus page. Or, for more stroke-focused content, check out our stroke clinical focus page.Episode Breakdown: 1:20 – Background on the multicenter study 3:30 – Goals of the study and main findings 5:25 – Surprising findings from the study 6:50 – The understanding of this association in clinical care 9:25 – Neurology News Minute 11:55 – Current state of prognostication post stroke 16:50 – The lack of standardized approach to monitoring 20:50 – Lingering needs for future studies 22:55 – Closing thoughts This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts New Drug Application for Duchenne Therapy Vamorolone Enrollment for Pivotal Phase 3 PHOENIX Study of AMX0035 Completed Alzheimer’s Association Panel Offers Considerations for New Definition of Meaningful Change in Drug Trials Sanofi Discontinues Phase 3 Study of Tolebrutinib in Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES1. Atuesta FC. Seizures After Ischemic Stroke: A Matched Multicenter Study. Presented at: AES Annual Meeting; December 2-6, 2022; Nashville, TN, and virtual. SIG.2. Ferreira-Atuesta C, Döhler N, Erdélyi-Canavese B, et al. Seizures after Ischemic Stroke: A Matched Multicenter Study. Ann Neurol. 2021;90(5):808-820. doi:10.1002/ana.26212

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease (PD), some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more. Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page, or for more PD-focused content, check out our disease spotlight on Parkinson disease. Episode Breakdown: 1:20 – Lingering unmet needs in Parkinson disease management 3:10 – The advances in identifying therapeutic targets in PD 4:25 – Bridging the gap to more effective long-term treatment 6:00 – Overview of IPX203 and its potential to treat PD 7:45 – Neurology News Minute 10:15 – Possible advantages of IPX203 13:25 – Safety profile of IPX203 in clinical development 15:50 – The importance of addressing dose-wearing off 16:40 – Closing thoughts This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neurelis Files IND for Potential First Therapy to Treat Cerebral Cavernous Malformations CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845 Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Sarah Boyce, president and CEO of Avidity Biosciences, who shared insight into the company's ongoing work with its antibody oligonucleotide conjugates (AOC) platform and the focus on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) treatments, as well as the challenges with developing successful RNA therapies, and more. Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® neuromuscular clinical focus page: neurologylive.com/clinical/neuromuscular Episode Breakdown: 1:20 – Current limitations with RNA therapies 4:50 – The decision to focus on rare genetic muscle diseases 7:45 – The patient needs in DM1, FSHD, and DMD 9:05 – Neurology News Minute 12:25 – Other clinical areas of focus and collaboration for Avidity 14:10 – Upcoming data presentations planned for 2023 in DMD and myotonic dystrophy 16:15 – The benefits of collaboration in the rare disease community 18:15 – Looking ahead to the future of therapies in rare muscular disease This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple Sclerosis FDA Clears First Stroke-Specific Radial Access Platform for Mechanical Thrombectomy FDA Designates Myasthenia Gravis Agent Rozanolixizumab Application for Priority Review FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease FDA Accepts sBLA for Revance’s Cervical Dystonia Treatment DaxibotulinumtoxinA Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this episode, we're covering the recent approval of lecanemab (Leqembi; Eisai) in Alzheimer disease. Offering commentary is Sharon Cohen, MD, FRCPC, a behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of the antiamyloid agent. Lecanemab was approved via the accelerated approval pathway, with the application supported by data from the phase 2b proof-of-concept clinical trial, known as Study 201 (NCT01767311). The pivotal phase 3 Clarity AD trial (NCT03887455) is anticipated to serve as supplementary data and is pending review by the FDA.For more of NeurologyLive®'s coverage of lecanemab's approval, head here: FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease For more coverage of Alzheimer disease and dementia, head to NeurologyLive®'s Alzheimer & Dementia clinical focus page.Episode Breakdown: 0:30 – Lecanemab (Leqembi; Eisai) approved for Alzheimer disease 1:35 – Sharon Cohen, MD, FRCPC, on the approval 3:15 – Supporting context on the accelerated approval pathway for lecanemab 4:50 – Questions about access amid current CMS guidance 6:25 – Data from the supporting phase 2 study, Study 201 7:15 – Safety and the 3 patient deaths reported in the clinical trial program Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES1. FDA grants accelerated approval for Alzheimer's disease treatment. FDA. News release. January 6, 2023. Accessed January 9, 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more. Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023. In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group. Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia/Alzheimer clinical focus page: neurologylive.com/clinical/dementia-alzheimer Episode Breakdown: 1:20 – Lecanemab's safety profile from Clarity AD 4:15 – Amyloid-related imaging abnormalities and lecanemab use 6:40 – The landscape of Alzheimer disease therapeutics 8:10 – Neurology News Minute 10:15 – What research has revealed about treatment approaches 13:00 – How clinical trials have evolved in dementia research 14:40 – The possibility of induction therapy in Alzheimer disease 16:30 – Looking ahead to the next steps in treatment development 18:00 – Progress toward treating Alzheimer disease earlier This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment Seizure-Free Days and Duration Intervals Increased with Fenfluramine in Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE 1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics. Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus page: neurologylive.com/clinical/movement-disorders Episode Breakdown: 1:20 – An overview of the state of virtual reality in medicine 2:20 – The Cleveland Clinic Virtual Reality Shopping platform 6:45 – The importance of mimicking the details of reality 8:05 – Misconceptions and surprises with VR for Parkinson disease 11:45 – Neurology News Minute 15:05 – How VR can be used in prodromal Parkinson disease 19:00 – Biomarkers for Parkinson disease 21:15 – Using VR as a targeted therapy 23:20 – The opportunity in medicine with VR systems This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation Duchenne Gene Therapy SRP-9001 Wins Priority Review Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with George Small, MD, an adult neurologist at Allegheny Health Network, who discussed the state of care for myasthenia gravis and its recent success, the corresponding changes to patient care, and the current era of treatment that the field has entered, among other topics.Looking for more myasthenia gravis discussion? Check out this NeurologyLive® Peers & Perspectives series, featuring James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN: Updates in the Management of Myasthenia Gravis Peers and PerspectivesEpisode Breakdown: 1:15 – The perspective on the current state of care in myasthenia gravis 4:05 – The rapidly evolving treatment landscape 6:40 – Allegheny Health Network's approach to myasthenia gravis care 10:05 – Treatment selection among patient groups 15:45 – Neurology News Minute 18:45 – Current challenges and adjustments with treatments 21:20 – Nonpharmacologic approaches to myasthenia gravis 26:55 – Challenges for patients and education around treatment access 28:35 – The future of myasthenia gravis care This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neurosteer Single-Channel EEG Platform Cleared by FDA Neurocrine Biosciences Submits Supplemental NDA for Valbenazine in the Treatment of Huntington Disease Chorea FDA Refuses to File BrainStorm’s BLA for NurOwn Mesenchymal ALS Therapy FDA Accepts NDA for Parkinson Disease Treatment IPX203 FDA Accepts NDA for Myasthenia Gravis Treatment Zilucoplan Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with a number of experts in the clinical care of MS who were in attendance at the 2022 ECTRIMS Congress, including Darin T. Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center; Federica Picariello, PhD, a health psychologist and postgraduate research associate at King's College London; Brenda Banwell, MD, chief of the Division of Neurology and codirector of the Neuroscience Center at the Children's Hospital of Philadelphia; Riley Bove, MD, associate professor of neurology, University of California, San Francisco; Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research Unit at the University of Melbourne, and head of the MS Centre at the Royal Melbourne Hospital; and Marisa McGinley, DO, a neurologist at the Mellen Center for MS at Cleveland Clinic. Click here for more coverage of ECTRIMS 2022.Episode Breakdown: 1:15 – Darin Okuda, MD, on the implications of the ARISE data in RIS 5:50 – Federica Picariello, PhD, on addressing fatigue and its mechanisms 10:40 – Brenda Banwell, MD, on advances in pediatric-onset MS 16:05 – Riley Bove, MD, on treatment NMOSD in pregnancy and post partum 21:30 – Tomas Kalincik, MD, PhD, on stem cell transplantation in MS 27:00 – Marisa McGinley, DO, on the optimal experience of teleneurology This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.comThanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with the chairs of the recently hosted International Congress on the Future of Neurology (IFN), including Stephen Krieger, MD, professor of neurology and neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai; Richard Isaacson, MD, director of the Center for Brain Health at the Florida Atlantic University Schmidt College of Medicine; and Jessica Ailani, MD, associate professor of neurology and director of the MedStar Georgetown Headache Center. They joined the show to recap their experience at the 2022 IFN meeting, discuss the value of cross-specialty interactions, share their perspective on the future of their fields, and more. To learn more about the Congress and other Physician's Education Resource CME activities, visit gotoper.com. Episode Breakdown: 1:15 – Richard Isaacson, MD, on his experience 3:20 – Stephen Krieger, MD, on his experience 6:20 – Jessica Ailani, MD, on her experience 9:45 – Krieger on the benefits of cross-specialty interactions 11:25 – Isaacson on the concept of earlier identification of disease 14:25 – Ailani on increasing diversity and discussion across neurology 16:00 – Krieger on the takeaways from COVID-19 in multiple sclerosis 18:55 – Ailani on the challenges of comorbidity and telemedicine 20:55 – Isaacson on the need to focus on the future of neurology This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Yuri Maricich, MD, MBA, internal medicine physician, and chief medical officer and head of development, Pear Therapeutics. He joined the show to discuss the current use of digital therapeutics in insomnia such as cognitive behavioral therapy, the state of education and treatment for the sleep disorder, some of the challenges in care, and more.Episode Breakdown: 1:15 – The positives of digital therapeutics in insomnia care 3:50 – Overview of a recent study from Maricich and colleagues 8:40 – Prioritization of sleep in clinical care 11:20 – Lack of clinical use of prescription digital therapeutics 13:05 – Neurology News Minute 15:30 – Differences for CBT-I among treatment-naïve individuals 18:05 – Use of CBT-I as a supplementary treatment tool 20:10 – Research needs and ongoing efforts 23:15 – What clinicians need to know about CBT-I and digital therapeutics 25:50 – Closing thoughts This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Alzheimer Disease Agent Lecanemab Shows Reduction in CDR-Sum of Boxes in Clarity AD Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial AMX0035 Approved for the Treatment of ALS CNM-Au8 Shows Survival Benefit in HEALEY ALS Trial, But Fails to Meet End Points Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES1. Forma F, Knight TG, Thorndike FP, et al. Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia. Clinicoecon Outcomes Res. 2022;14:537-546. doi:10.2147/CEOR.S368780

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Ambereen Mehta, MD, MPH, palliative care physician, and assistant professor of medicine, Johns Hopkins Bayview Medical Center. She joined the show to discuss palliative care and its evolving role in the care paradigm for patients with chronic neurologic disease, as well as its history in the United States, how it differs from hospice care, and more. To learn more about neuropalliative care, head to our International Neuropalliative Care Society (INPCS) partner page, or click here to learn more about the INPCS 2022 Annual Meeting. Episode Breakdown: 1:15 – Overview of palliative care and its purpose 5:40 – Differences between hospice and palliative care 7:55 – History of palliative care in the United States 12:25 – Palliative care's fit in neurologic care 15:10 – Neurology News Minute 17:10 – Benefits of care for caregivers 21:15 – Palliative care resources and societies 22:30 – Neuropalliative care and its current goals 26:30 – Benefits for clinicians of implementing neuropalliative care 30:20 – Recommendations for physicians 36:00 – Tips for trying palliative care practices and findings resources This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts Application for Trofinetide in Rett Syndrome LIFT-AD Study Amended to Assess Alzheimer Disease Agent Fosgonimeton as Monotherapy Tolerizing MS Vaccine Displays Efficacy in Model of Relapsing-Remitting Multiple Sclerosis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Shemme AJ, Phillips JN, Bloise R, Koehler TJ, Gorelick PB, Francis BA. The Impact of a Neurocritical Care and Neuropalliative Collaboration on Intensive Care Unit Outcomes. Am J Hosp Palliat Care. 2022;39(6):687-694. doi:10.1177/10499091211060055 2. Mehta AK, Wright SM, Wu DS, Harris CM. Palliative Care Involvement in Patients Hospitalized in the United States with Aneurysmal Subarachnoid Hemorrhage. J Palliat Med. 2021;24(10):1555-1560. doi:10.1089/jpm.2021.0116 3. Williamson TL, Adil SM, Shalita C, et al. Palliative Care Consultations in Patients with Severe Traumatic Brain Injury: Who Receives Palliative Care Consultations and What Does that Mean for Utilization? Neurocrit Care. 2022;36(3):781-790. doi:10.1007/s12028-021-01366-2 4. Bužgová R, Kozáková R, Bar M. The effect of neuropalliative care on quality of life and satisfaction with quality of care in patients with progressive neurological disease and their family caregivers: an interventional control study. BMC Palliat Care. 2020;19(1):143. doi:10.1186/s12904-020-00651-9 5. Mehta AK, Jackson NJ, Wiedau-Pazos M. Palliative Care Consults in an Inpatient Setting for Patients With Amyotrophic Lateral Sclerosis. Am J Hosp Palliat Care. 2021;38(9):1091-1098. doi:10.1177/1049909120969959 6. Lou W, Granstein JH, Wabl R, Singh A, Wahlster S, Creutzfeldt CJ. Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury. Neurocrit Care. 2022;36(2):504-510. doi:10.1007/s12028-021-01335-9. 7. Miyasaki JM, Kluger BM (ed). Handbook of Clinical Neurology. Neuropalliative Care - Part I. 2022;190:2-243 8. Lou W, Granstein JH, Wabl R, Singh A, Wahlster S, Creutzfeldt CJ. Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury. Neurocrit Care. 2022;36(2):504-510. doi:10.1007/s12028-021-01335-9 9. Phillips JN, Besbris J, Foster LA, Kramer NM, Maiser S, Mehta AK. Models of outpatient neuropalliative care for patients with amyotrophic lateral sclerosis. Neurology. 2020;95(17):782-788. doi:10.1212/WNL.0000000000010831

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Christopher Elder, MD, clinical assistant professor of neurology, Comprehensive Epilepsy Center, NYU Langone Health. He joined the show to talk about the latest updates in the care of patients with epilepsy, the clinical therapeutic pipeline developments on the horizon, and the need to continue stressing conversations around sudden unexpected death in epilepsy (SUDEP).Episode Breakdown: 1:15 – The rise of neurostimulation in epilepsy care 4:00 – Increasing implantation of minimally invasive options 5:15 – Patient reception to nontherapeutic approaches 7:45 – The impact of cenobamate (Xcopri; SK Life Science) on the paradigm 10:35 – Managing refractory epilepsy 12:00 – Upcoming options for those with generalized epilepsy 13:50 – Neurology News Minute 18:30 – Path forward for gene and cell therapies in epilepsy 21:00 – The need to improve early recognition of epilepsy 25:20 – Standardizing questionnaires and information for epilepsy 27:00 – The need to continue discussing SUDEP This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Midazolam Autoinjector for Status Epilepticus Sirolimus Topical Gel Available for Facial Angiofibroma Associated With Tuberous Sclerosis Complex FDA Lifts Hold on Phase 2 Trial of SRP-5051 in DMD Amenable to Exon 51 Skipping Philips Respironics Recalls Masks for BPAP and CPAP Machines After Safety Concerns FDA Advisory Committee Votes to Recommend AMX0035 for Treatment of ALS Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Chris Winter, MD, owner of Charlottesville Neurology and Sleep Medicine clinic and CNSM Consulting, and an author of several books on sleep. he shared his perspective on the state and prevalence of pediatric sleep disorders, how the current system of schooling affects children's sleep, and the trends that are occurring in sleep research and awareness.Episode Breakdown: 1:15 – Current conversations around school start times and sleep 5:25 – The role of virtual schooling in helping sleep 9:00 – Education about sleep for children, parents, and professionals 13:15 – The current trends in sleep-focused behaviors 14:30 – The prevalence and awareness of pediatric sleep disorders 16:35 – Neurology News Minute 19:30 – Improving sleep evaluation in daily clinical practice 24:00 – The trends in sleep medicine 26:30 – Leveraging the inherent attractiveness of sleep conversations 27:00 – Tips for the clinical community and self-advocacy This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Two Patient Deaths Reported With Zolgensma Administration in SMA Passage Bio Doses First Patient in Frontotemporal Dementia Gene Therapy Trial BLA Application to Be Submitted for ALS Agent NurOwn Following Phase 3 Statistical Corrections Jazz Initiates Trial Assessing Cannabidiol in Epilepsy With Myoclonic-Atonic Seizures Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Olwen C. Murphy, MBBCh, assistant professor of neurology, Johns Hopkins University; and Matthew R. Vogt, MD, PhD, assistant professor of pediatric infectious diseases, University of North Carolina at Chapel Hill. The pair spoke about the current clinical understanding of acute flaccid myelitis (AFM) and the existing treatment approach, as well as the current guidelines and the need to improve awareness ahead of the peak infection months in autumn. Click here for AFM resources: CDC – Acute Flaccid Myelitis SRNA – Acute Flaccid Myelitis Episode Breakdown: 1:15 – Background on AFM from the neurology perspective 3:50 – Background on AFM from the infectious disease perspective 6:10 – Ongoing work and research into AFM cases 9:15 – The evolution of the clinical care of patients with AFM 13:00 – The diagnostic approach and guidelines for AFM 16:05 – Neurology News Minute 19:00 – State of care and treatment approaches 21:45 – The importance of recognition of AFM 26:50 – Testing and differential diagnosis of AFM 32:30 – Message for the clinical community around awareness This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Significant Correlations Identified Between Mental Health and Migraine FDA Issues Second CRL for Pimavanserin, Now for the Treatment of Alzheimer Disease Psychosis ICER Releases Report Comparing Cost-Effectiveness of ALS Agents Oral Edaravone and AMX0035 FDA Extends Review of Omaveloxolone in Friedreich Ataxia Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Darin T. Okuda, MD, professor of neurology and director of Neuroinnovation and the Multiple Sclerosis & Neuroimmunology Imaging Program at The University of Texas Southwestern Medical Center at Dallas; and Karin Cook, senior vice president of medical strategy and clinical ethnographer, Heartbeat Medical Communications. The pair spoke about their research into the wasted costs associated with disease-modifying therapies (DMTs) for patients with multiple sclerosis, what they've observed at their center, the wide-reaching impact of this waste on the healthcare continuum, and the future solutions that are being worked on for this problem. Click here for more coverage of this story: Multiple Sclerosis DMT Waste Is Staggering, New Study Shows Wasted DMTs in Dr. Okuda's office [Image] Episode Breakdown: 1:45 – Background on the study conducted by Okuda et al. 4:05 – Perspective on the cost driven by DMT waste 6:30 – Current landscape of prescriptions and adherence in MS 8:35 – Disparities in MS treatment adherence 11:00 – The link to the physician-patient relationship 16:40 – The process of choosing a DMT and shared decision-making 23:00 – Neurology News Minute 25:45 – Finding solutions to the DMT waste problem 33:40 – The role of the individual neurologist and patient 38:30 – Access to specialist care and resources 42:40 – Building trust with patients and general medical mistrust 47:00 – Next steps and closing thoughts This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Zonisamide Oral Suspension FDA-Approved for Partial Seizures in Epilepsy FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy FDA Clears Rapid Hyperdensity Tool for Inclusion in RapidAI Platform for Neurovascular Conditions ALS Therapy Tofersen Has NDA Accepted by FDA, Granted Priority Review Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCE 1. Okuda DT, Burgess KW, Cook K, McCreary M, Winkler MD, Moog TM. Hiding in plain sight: the magnitude of unused disease-modifying therapies in multiple sclerosis and strategies for reducing the economic burden. Mult Scler Relat Disord. 2022;63:103920. doi:10.1016/j.msard.2022.103920

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Rajesh Pahwa, MD, professor of neurology, and director, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center. He spoke about the current state of treatment for essential tremor, including the therapeutic and surgical options for this population, and shared his perspective on the latest advances in clinical care and diagnosis, the role of the patient-physician relationship, and the research into the disease's underlying processes. Episode Breakdown: 1:25 – Overview of the current state of essential tremor care 7:05 – Changes in thinking about essential tremor 9:05 – Potential in the therapeutics pipeline 10:45 – Advances in the understanding of essential tremor 12:40 – Neurology News Minute 15:30 – The role of shared decision-making in care 18:50 – Surgical options for essential tremor treatment 22:00 – Education and diagnosis outside of movement specialists 24:00 – Advances on the horizon Check out Medical World News' Second Opinion only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Biogen, Alectos Announce Licensing Agreement for Parkinson Disease GBA2 Inhibitor AL01811 FDA Advisory Committee Agrees to Reconvene for Decision on ALS Treatment AMX0035 FDA Accepts BLA for Lecanemab in Alzheimer Disease, Sets PDUFA Date for January 2023 FDA Places Clinical Hold on Phase 2/3 ReMEDy2 Trial of DM199 in Acute Ischemic Stroke Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Serena L. Orr, MD, MSc, a pediatric neurologist and headache specialist at the University of Calgary and Alberta Children's. She spoke about the recent work she's done looking into mental health conditions among pediatric patients with migraine, as well as how the field has progressed in managing the disease and advocating for these individuals. Episode Breakdown: 1:25 – Overview of systematic review of depressive and anxiety symptoms in pediatric migraine 5:30 – Clinical implications of the data and the need for advocacy for this population 8:50 – Possible differences between children and adolescents 10:15 – Remaining questions for this area of research 13:20 – The needs from a research funding perspective 15:05 – Neurology News Minute 17:20 – Shifting the paradigm of pediatric headache research 21:35 – Challenges in awareness despite patient population size 24:15 – Exposure to headache medicine education among trainees 26:25 – Conducting clinical trials in pediatric migraine Check out Medical World News' Second Opinion only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Advisory Committee Votes Down Pimavanserin's Efficacy in AD Psychosis Ahead of PDUFA Parkinson Disease Symptom Data Tool StrivePD Receives FDA Clearance AbbVie Submits Supplemental New Drug Application for Atogepant in Chronic Migraine FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns FDA Pauses Tolebrutinib Trials in MS, Myasthenia Gravis Over Liver Injuries Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a number of individuals who presented data and spoke at the Consortium of Multiple Sclerosis Centers Annual Meeting, on topics ranging from the examination of longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders, JZP-258’s impact on the treatment of patients with idiopathic hypersomnia, and the understanding of the signs and risks associated with sleep disorders and Alzheimer disease. This episode is brought to you by Medical World News Second Opinion. Check out new episodes every Tuesday and Thursday only on medicalworldnews.com. Those featured include (in order of appearance): Afsara Zaheed, graduate student, University of Michigan Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, and associate clinical professor, Medical University of South Carolina Ruth Benca, MD, PhD, professor and chair, Psychiatry & Human Behavior, Wake Forest School of Medicine Episode Breakdown: 1:30 – Afsara Zaheed on the longitudinal patterns of difficulties initiating sleep, the associations with subsequent memory trajectories, and whether associations differ across non-Hispanic Black and White men and women. 6:00 – Richard Bogan, MD, FCCP, FAASM, on two post hoc analyses that explored treatment response for low-sodium oxybate based on the 14-item Idiopathic Hypersomnia Severity Scale and the 8-item, self-reported Epworth Sleepiness Scale. 12:05 – Ruth Benca, MD, PhD, on the precursor sleep issues to Alzheimer disease, the differences in sex and race, and the critical need to treat sleep disorders early as possible. Click here for more coverage of SLEEP 2022. Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. Update Description

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we mark 1 year since the FDA granted accelerated approval to aducanumab (Aduhelm; Biogen), the first approval in Alzheimer disease since 2003. This episode offers an abridged recap of the events that have taken place over the course of its clinical journey, and in the year since that decision. Later this month, the June 2022 issue of NeuologyLive® will include a cover story that features a more in-depth and extensive review of the aducanumab saga and its implications for the clinical community from David S. Knopman, MD, a portion of which is featured in this episode. The June 2022 issue, including Dr. Knopman's story, can be viewed here: www.neurologylive.com/journals/neurologyliveThanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. This episode featured the songs "Dreams" and "Stronger" by Alan Špiljak, obtained under the CC BY-NC-ND 4.0 license.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with a number of individuals who presented data and spoke at the Consortium of Multiple Sclerosis Centers Annual Meeting, on topics including women with multiple sclerosis, the importance of measuring cognition in MS, the characterization of relapse attacks in neuromyelitis optical spectrum disorder, the use of spinal cord atrophy as a biomarker of disease progression, the potential to save time reviewing complex patient histories, and more.This episode is brought to you by Medical World News Second Opinion. Check out new episodes every Tuesday and Thursday only on medicalworldnews.com.Those featured include (in order of appearance): Riley Bove, MD Blake E. Dewey, PhD Bruce Cree, MD, PhD, MAS John DeLuca, PhD Shuvro Roy, MD Tanuja Chitnis, MD Episode Breakdown: 2:00 – Riley Bove, MD, on the conversations that women with multiple sclerosis have about disease-modifying therapies on social media platforms. 5:10 – Blake Dewey, PhD, on the efforts to improve the uptake in the use of spinal cord atrophy as a marker of disease progression. 8:45 – Bruce Cree, MD, PhD, MAS, on the latest data from the N-MOmemtum study in neuromyelitis optica spectrum disorder. 13:05 – John DeLuca, PhD, on the importance of measuring cognition longitudinally in patients with multiple sclerosis. 17:10 – Shuvro Roy, MD, on how the MS Smartform might be able to save physicians time in reviewing complex patient histories. 20:30 – Tanuja Chitnis, MD, on the use of foralumab in an older patient with nonactive secondary progressive multiple sclerosis. Click here for more coverage of CMSC 2022.Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Matthew B. Harms, MD, associate professor of neurology, Columbia University, and medical consultant and care center director, Muscular Dystrophy Association (MDA). He spoke about the progress that the field has seen in recent years in improving the genetic understanding of amyotrophic lateral sclerosis (ALS) and the role that big data can play in care, as well as shared his perspective on the impact that advocacy efforts have had on these advances. Episode Breakdown: 2:05 – Major progress in ALS in recent years 4:35 – Key steps forward in genetic testing 7:25 – The understanding of genetics in ALS 9:20 – The role of databases in the care paradigm 11:35 – Neurology News Minute 15:25 – Advocacy's role in the last decade 18:40 – The state of clinical trials for ALS 20:40 – The pipeline of therapies and the future of treatment 24:50 – Importance of continued advocacy for ALS Check out Medical World News' Second Opinion only at medicalworldnews.comThe stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: National Institutes of Health Launches Phase 1 Trial to Study Epstein-Barr Virus Vaccine Eisai Completes Rolling BLA Submission for Lecanemab to Treat MCI, Alzheimer Disease FDA Approves Oral Version of Edaravone for ALS Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Jessica Ailani, MD, director, MedStar Georgetown Headache Center, and associate professor of neurology, MedStar Georgetown University Hospital. She spoke about some recent data in headache medicine that has provided evidence of the in-clinic experience and how the migraine treatment landscape has shifted, and what challenges need to be addressed to achieve the goal of developing personalized treatment regimens for patients. Episode Breakdown: 1:25 – Migraine highlights from the 2022 AAN Annual Meeting. 5:00 – Atogepant post hoc analyses showing dose-dependent weight loss. 9:25 – Rimegepant data and optimizing available treatments for quality of life. 12:50 – Current day-to-day challenges in migraine care. 15:10 – Neurology News Minute 18:50 – Progress made toward increasing migraine training and education. 22:45 – Other specialty's understanding of the migraine population. 27:35 – The importance of behavioral interventions in migraine. 32:05 – Looking ahead to the future of care. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Axsome Issued CRL for AXS-07 in Acute Migraine Treatment FDA Approves Ravulizumab for Adults With Generalized Myasthenia Gravis FDA Permits Marketing for Plaque-Detecting Diagnostic Test for Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Yasar Torres-Yaghi, MD, director, Parkinsonism and Dementia Clinic, assistant professor of neurology, MedStar Georgetown University Hosptial, about the current state of therapeutic intervention for movement disorders, and this year's first annual Advanced Therapeutics in Movement & Related Disorders™ Congress, being put on by the PMD Alliance. Click here to register and find more information on the ATMRD Congress. Episode Breakdown: 3:15 – Background on the new ATMRD Congress. 6:20 – Rates of adoption of novel therapeutics for Parkinson disease. 9:35 – What attendees should expect from the Congress this year. 11:20 – The need for a multidisciplinary approach to movement disorders and the multidisciplinary features of the Congress. 12:35 – Neurology News Minute 16:30 – Education and understanding about the optimal utilization of advanced therapies in Parkinson disease. 19:10 – Ongoing trends and conversations in the movement disorder field. 21:30 – Closing thoughts. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Boston Scientific’s STIMVIEW XT Guided Imaging Software for DBS FDA Extends Review of Vutrisiran for ATTR Amyloidosis 3 Months, Now Expected in July 2022 Higher-dose Erenumab Shows Better Prevention of Progression, Rationale Provided for Initiation at High Dose Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a number of individuals who presented data and spoke at the American Academy of Neurology Annual Meeting, on topics ranging from COVID-19's clinical presentation, overall trends in the care of patients with multiple sclerosis, the potential of regenerative medicine in traumatic brain injury, the real-world and long-term use of new therapy for Lennox-Gastaut syndrome, the optimal timing for the newest therapy in neuromyelitis optica spectrum disorder, the Axon Registry and incorporating EHR information into its data collection, and the impact of the pandemic on clinician burnout and mental health. Note: As part of AAN policy for the Annual Meeting, all individuals were asked to remain masked throughout the week, so there may be some moments of muffled noises as participants adjust or shift their masks. Those featured include (in order of appearance): Jennifer Frontera, MD Stephen Krieger, MD Peter McAllister, MD Kelly Knupp, MD, MSCS Bruce Cree, MD, PhD, MAS Shrujal Baxi, MD, MPH Indu Subramanian, MD. Episode Breakdown: 1:50 – Jennifer Frontera, MD, on the long-term data collected on COVID-19 post-infection neurological sequelae. 9:55 – Stephen Krieger, MD, on the trends in thinking about multiple sclerosis pathogenesis and quality of life. 14:05 – Peter McAllister, MD, on the phase 2 STEMTRA trial of stem cell therapy in patients with traumatic brain injury. 16:45 – Kelly Knupp, MD, MSCS, on the long-term use of fenfluramine in Lennox-Gastaut syndrome and clinical pearls on titration. 19:00 – Bruce Cree, MD, PhD, MAS, on the effect of inebilizumab in patients with neuromyelitis optica spectrum disorder regardless of disease duration. 21:05 – Shrujal Baxi, MD, MPH, on the AAN's Axon Registry and how Verana Health is playing a role in data collection. 23:55 – Indu Subramanian, MD, on the effects of COVID-19 on physicians and clinicians and the difficulties that have challenged the field. Click here for more coverage of AAN 2022. Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this episode, we're covering the recent approvals of ganaxolone (Ztalmy; Marinus Pharmaceuticals) in cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, also known as CDD, as well as fenfluramine (Fintepla; Zogenix/UCB) in Lennox-Gastaut syndrome (LGS). Offering commentary is a pair of experts. The first is Scott Demarest, MD, MSCS, neurologist and clinical director of precision medicine, Children’s Hospital Colorado, and assistant professor of pediatrics-neurology, University of Colorado, and an investigator of the Marigold trial (NCT03572933). The second is Kelly G. Knupp, MD, MSCS, FAES, pediatric neurologist, Children's Hospital Colorado, and associate professor of pediatrics-neurology, University of Colorado, and an investigator of Study 1601 (NCT03355209).For more of NeurologyLive®'s coverage of ganaxolone's approval, head here: Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder. For more of NeurologyLive®'s coverage of fenfluramine's approval, head here: Fenfluramine FDA-Approved for Treatment of Lennox-Gastaut Syndrome. For more coverage of epilepsy and seizure disorders, head to NeurologyLive®'s Epilepsy clinical focus page.Episode Breakdown: 0:30 – Ganaxolone (Ztalmy; Marinus) approved for CDD 2:30 – Scott Demarest, MD, with his reaction to the approval 3:00 – Data from the Marigold study of ganaxolone 4:45 – Safety profile of ganaxolone in development 5:10 – Demarest on the landscape of care for CDD 6:20 – Clinical takeaways ahead of DEA scheduling for ganaxolone 8:40 – Fenfluramine (Fintepla; Zogenix/UCB) approved for LGS 10:55 – Kelly Knupp, MD, with her reaction to the new indication 11:30 – Efficacy data on fenfluramine in LGS 13:50 – Safety profile in LGS and Dravet syndrome 16:05 – Knupp on the potential to improve quality of life and optimal use Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES1. Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. News release. March 18, 2022. Accessed March 21, 2022. https://www.businesswire.com/news/home/20220318005282/en/Marinus-Pharmaceuticals-Announces-FDA-Approval-of-ZTALMY%C2%AE-ganaxolone-for-CDKL5-Deficiency-Disorder2. FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS). News release. UCB. March 28, 2022. Accessed March 28, 2022. https://finance.yahoo.com/news/fintepla-fenfluramine-oral-solution-now-050000058.html

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Friedmann Paul, MD, head, Clinical Neuroimmunology Research Group, NeuroCure Clinical Research Center, and head, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité–Universitätsmedizin Berlin. He shared his perspective on the state of care in neuromyelitis optica spectrum disorder (NMOSD), the need to raise awareness for symptomatic care and patient challenges, and the potential of novel therapeutic approaches to improve care.Episode Breakdown: 2:00 – State of diagnosis and care for NMOSD and similar disorders 6:00 – Role of NMOSD Awareness Month and advocacy efforts 8:45 – Current challenges with symptomatic management 11:20 – Multidisciplinary communication, coordination, and collaboration 13:05 – Neurology News Minute 16:45 – The potential of self-tolerization and curing NMOSD 19:05 – Nonpharmacologic approaches to care 20:40 – The need to improve physician awareness and education 22:45 – Advice for communicating the diagnosis to patients 24:45 – The need for patient advocacy groups The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Donepezil Transdermal System Wins FDA Approval to Treat Alzheimer Disease Dementia Sarepta Details Phase 3 EMBARK Study in DMD Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Richard K. Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, and associate clinical professor, Medical University of South Carolina. He spoke to the current prevalence and impact of narcolepsy and offered insight into the link between the sleep disorder and cardiovascular health.Episode Breakdown: 1:40 – Overview of narcolepsy 5:00 – Manifestation of narcolepsy and misdiagnosis rates 8:35 – Link between cardiovascular health and narcolepsy 12:10 – Tips to improve healthier behavioral habits 16:10 – Resources for physicians Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Seema Khosla, MD, FCCP, FAASM, medical director, North Dakota Center for Sleep. She shared her insight into the American Academy of Sleep Medicine's ongoing initiative to switch to a fixed standard time year-round, as well as offered her perspective on the current state of care for sleep disorders.Episode Breakdown: 1:30 – AASM's position statement on daylight saving time 3:15 – The impact of daylight saving time on circadian rhythm 5:30 – Patient education on sleep and daylight saving 6:40 – What can be learned from similar attempts to address sleep issues 10:00 – Evidence in favor of fixed-standard time 11:45 – Neurology News Minute 14:50 – The state of sleep in the US 19:15 – Physicians' relationship with sleep education 23:20 – Importance of World Sleep Day and awareness 25:30 – Advice for inquiring about patient sleep The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Announces Phase 3 SKYLINE Trial of Gantenerumab in Alzheimer Disease FDA Approves Saluda’s Evoke Spinal Cord Stimulation System for Chronic Intractable Pain IND Application Accepted for Phase 2b Trial of NOE-101 in Trigeminal Neuralgia Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES 1. Rishi MA, Ahmed O, Perez JHB, et al. Daylight saving time: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2020;16(10):1781-1784. doi:10.5664/jcsm.8780 2. AASM calls for end of seasonal time changes ahead of “springing forward”. News release. AASM. March 9, 2022. Accessed March 10, 2022. https://aasm.org/aasm-calls-for-end-of-seasonal-time-changes-ahead-of-springing-forward/

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Konstantin Karmazin, MD, clinical neurologist, and chief medical officer, Prime PD. He discussed the virtual wellness studio that was recently launched, its capabilities and goals for the community of patients with Parkinson disease, and its benefits for physicians. Episode Breakdown: 1:25 – Background on Prime PD 5:00 – The digital wellness studio's programs for PD 9:20 – Future aims for additional disease states 12:00 – Neurology News Minute 14:20 – Potential to incorporate advanced practice clinicians and specialists 17:15 – Feedback from patients and physicians 22:30 – How physicians can get involved and/or utilize Prime PD To learn more about Prime PD, check out their website: www.primepd.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: High-Dose ACI-35.030 Shows Positive Phase 1b/2a Interim Data as Alzheimer Vaccine Acadia Resubmits sNDA for Pimavanserin to Treat Alzheimer Disease Psychosis Tolebrutinib Shows Favorable Long-Term Safety, Efficacy in Relapsing MS Open-Label Extension Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Dhanashri P. Miskin, MD, clinical assistant professor of neurology, Thomas Jefferson University Hospitals. She offered her insight into the role that cognitive impairment plays as a symptom of multiple sclerosis (MS), the current approach to treatment and management for patients, and what challenges remain for the field to address.Episode Breakdown: 1:25 – Background on cognitive symptoms of MS 4:25 – Prevalence of cognitive issues for patients 6:05 – Current understanding of the driving factors of cognitive issues 8:15 – Management practices and approaches to prevention 13:20 – Tips on talking to patients about preventive approaches 16:30 – Neurology News Minute 19:10 – Challenges in helping patients adjust behavioral habits 23:20 – Advances in tracking cognitive changes in MS 28:00 – Potential role of EBV infection on these processes 30:35 – Most glaring need in addressing cognitive issues in MS 33:55 – COVID's impact on MS Want to learn more about EBV and MS? Click here to register for free for an in-depth NeurologyLive®panel discussion including Scott Newsome, DO (moderator); Alberto Ascherio, DPh, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD.The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: 1-Week Epworth Sleepiness Scale for Children and Adolescents Validated for Pediatric Narcolepsy Baclofen Oral Suspension Approved for Treatment of Spasticity in Multiple Sclerosis Phase 2 Study of CY6463 in Alzheimer Disease With Vascular Pathology Initiated Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Bridget A. Bagert, MD, MPH, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of the Epstein-Barr virus (EBV)-targeted agent, ATA188 (Atara Biotherapeutics). She offered her perspective on the recent data from Ascherio et al on the relationship between EBV and multiple sclerosis (MS) that suggest it may be a root cause of the disease, as well as background on the decades of research that have led to this point and the potential of therapies that target EBV and the B cells it infects for patients with MS. Episode Breakdown: 1:25 – Background and historical data on EBV and MS 5:15 – The role B cells play in MS and EBV infection 10:20 – The current understanding of EBV as a cause of MS 14:20 – Neurology News Minute 18:05 – Immediate research needs in this area 21:00 – The clinical community’s view of this relationship 23:45 – ATA188 as an EBV-targeted approach to MS 30:00 – Closing thoughts Want to learn more about EBV and MS? Click here to register for free for an in-depth NeurologyLive®panel discussion including Scott Newsome, DO (moderator); Alberto Ascherio, DPh, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Designing New Phase 2 Trial of Tominersen in Huntington Disease Risdiplam Gets Priority Review for Presymptomatic SMA in Babies Under 2 Months Diverse Enrollment, Primary End Point Announced for Phase 4 ENVISION Study of Aducanumab Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Bar-Or A, Pender MP, Hodgkinson SJ, et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis. Presented at ECTRIMS Congress; October 13-15, 2021; Poster P638. 2. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. Published online January 13, 2022. doi:10.1126/science.abj8222

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Anne-Maree Kelly, MD, MClinEd, FACEM, senior emergency physician, Western Health; director, Joseph Epstein Centre for Emergency Medicine Research; professorial fellow, the University of Melbourne; and adjunct professor, Australian Centre for Health Law Research, Queensland University of Technology. She shared her clinical experience treating patients with headache and migraine in the emergency department (ED), offering insight into the factors that influence patient outcomes and the vital need for consensus international guidelines for ED migraine care.Episode Breakdown: 1:35 – Topline findings of a study of migraine in the ED 4:55 –The current state of guidelines for treatment and imaging 6:50 – Take-home points for emergency physicians 10:20 – State of education on headache and migraine in emergency medicine 11:40 – Neurology News Minute 14:40 – The stakeholders for developing consensus guidelines 16:30 – Additional research that is needed 19:20 – The role of experience in managing headache disorders in the ED The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: 5-SENSE Score Validated for Seizure-Onset Zone Identification, May Improve Patient Eligibility for Epilepsy Surgery FDA Approves Daridorexant for Insomnia Treatment CMS Releases Proposed Decision for Aducanumab Coverage in Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCEKelly AM, Kuan WS, Chu KH, et al. Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)–a multinational observational study. Headache. 2021;61(10):1539-1552. doi:10.1111/head.14230

Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this episode, we're covering the recent approval of daridorexant (Quviviq; Idorsia) for the treatment of insomnia. Offering commentary is Thomas Roth, PhD, director, Sleep Disorders and Research Center, Henry Ford Hospital; professor of psychiatry, Wayne State University School of Medicine; and clinical professor of psychiatry, University of Michigan College of Medicine; and an investigator in the clinical development studies.For more of NeurologyLive®'s coverage of daridorexant's approval, head here: FDA Approves Daridorexant for Insomnia Treatment. For more coverage of sleep disorders, head to NeurologyLive®'s Sleep Medicine clinical focus page.Episode Breakdown: 0:30 – Daridorexant (Quviviq; Idorsia) approved for insomnia 2:20 – Thomas Roth, PhD, with the clinical takeaways 4:30 – Efficacy data from Study 1 and Study 2 6:10 – Thomas Roth, PhD, on the efficacy profile 8:20 – Safety data from Study 1 and Study 2 9:00 – Thomas Roth, PhD, on the safety profile Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCEIdorsia receives US FDA approval of Quviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed January 10, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Jennifer Majersik, MD, MS, chief, division of vascular neurology, and professor of neurology, University of Utah, who along with 9 other colleagues, authored a report from the American Academy of Neurology (AAN) 2019 Transforming Leaders Program on the ongoing shortage of physicians in neurology. She offered her perspective on the challenge and how it can be addressed from an individual and institutional level.Episode Breakdown: 3:40 – Overview of the shortage in neurology 5:00 – Attracting new medical students to neurology 7:05 – The role of AAN and medical organizations 9:35 – The role of the individual neurologist 11:50 – The increase in fellowship training in neurology 14:00 – The impact on patient care Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES 1. Majersik JJ, Ahmed A, Chen IA, et al. A shortage of neurologists – we must act now: A report from the AAN 2019 transforming leaders program. Neurology. Published online April 30, 2021. doi:10.1212/WNL.00000000000121112. AAMC Report Reinforces Mounting Physician Shortage. News release. AAMC. June 11, 2021. Accessed December 30, 2021. https://www.aamc.org/news-insights/press-releases/aamc-report-reinforces-mounting-physician-shortage

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program (AD-CARE); William B. and Sheila Konar Professor of Psychiatry, School of Medicine and Dentistry, University of Rochester. He shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold.Episode Breakdown: 1:15 – Agents in late-stage development in Alzheimer disease 10:30 – Additional agents with promise in the pipeline 17:00 – Neurology News Minute 21:05 – The next big step forward in Alzheimer 31:10 – Learning from prior failures, improving diagnostics 45:00 – Looking back on the progress in 2021, and ahead to 2022 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: American Academy of Sleep Medicine Publishes Updated Recommendations on Referring OSA Candidates for Surgery Phase 3 Study of BXCL501 for Agitation in Alzheimer Disease Initiated FDA Accepts Ublituximab Biologics License Application for Relapsing MS Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Christina Szperka, MD, MSCE, assistant professor of neurology, and director, Pediatric Headache Program, Children's Hospital of Pennsylvania. She offered up her thoughts on the current state of clinical care and awareness of pediatric migraine and shared her insight into the changes the landscape of treatment has undergone.Episode Breakdown: 1:15 – The landscape of pediatric migraine 3:00 – Challenges in diagnosing pediatric migraine 5:00 – Parental and patient awareness of signs and symptoms 6:25 – Differences between adult and pediatric migraine 11:35 – Impact of new therapies for pediatric patients 15:00 – Neurology News Minute 17:35 – The day-to-day clinical care of pediatric migraine 20:40 – Medication adherence among children and teens with migraine 24:00 – Transitioning patients from pediatric to adult care 27:40 – Challenges in conducting pediatric migraine studies 30:40 – Biggest advances in the past year and amid COVID-19 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease Enrollment Complete for Phase 2 Study of ATH-1017 in Moderate Alzheimer FDA Accepts sNDA, Grants Priority Review to Fenfluramine for Lennox-Gastaut Syndrome Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Karl Doghramji, MD, professor of psychiatry and human behavior; professor of neurology; and medical director, Jefferson Sleep Disorders Center, at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health. He shared his perspective on the current state of care for sleep disorders, the impact of the pandemic on sleep in the US, and some of the recent advances in therapeutics and research. Episode Breakdown: 1:15 – The role of sleep in individuals' emotional and physical lives 5:40 – Current awareness about the health effects of poor sleep 8:15 – Clinical and commercial tools to measure sleep 10:45 – Recent advances in therapeutics for sleep disorders 15:20 – Tailoring specific therapies for specific patients 17:15 – Neurology News Minute 19:45 – Narcolepsy as a model for other sleep disorders 22:20 – Patient identification and differential diagnosis 25:40 – The sleep specialist's inclusion in the comprehensive care model 28:25 – Meeting the increasing demand for sleep specialists 30:40 – Sleep's role in dementia and cognition 33:50 – The state of sleep amid the COVID-19 pandemic The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Phase 3 PHOENIX Study of AMX0035 in ALS Gets Under Way FDA Approves First Oral Solution of Topiramate to Treat Epilepsy, Migraines Robert Califf, MD, Nominated by Biden Administration as Next FDA Commissioner Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Victor Sung, MD, director, UAB Huntington's Disease Clinic, codirector, UAB School of Medicine Neuroscience Module, and director, Birmingham VAMC Deep Brain Stimulation Program. Sung detailed data on the cost of genetic testing in HD that he and colleagues presented earlier this year at the International Parkinson and Movement Disorders Society Congress (MDS 2021), and the current utilization of testing in clinical practice.Episode Breakdown: 1:45 – Background on the genetic testing process 3:50 – Findings of the study presented at MDS 2021 7:30 – Future plans to evaluate genetic testing costs 11:30 – Current utilization of genetic testing for HD 14:10 – Neurology News Minute 18:05 – Raising awareness for genetic testing 21:25 – Biggest step forward in Huntington disease 25:10 – Takeaways from MDS 2021 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Cerezen Device Gets Breakthrough Designation in Alzheimer Disease, MCI Eli Lilly Initiates Rolling Submission for Donanemab in Early Alzheimer Disease Amylyx Submits New Drug Application for ALS Treatment AMX0035 Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCEMassey M, Orem T, Sung V. Cost of Predictive Genetic Testing for Huntington’s Disease at Centers of Excellence in the US. Presented at: MDS Congress 2021; September 17-22; Virtual. Poster 240.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Stephen Krieger, MD, professor of neurology, Icahn School of Medicine, and staff neurologist, Corinne Goldsmith Dickinson Center for MS, Mount Sinai. Krieger discussed the development of his topographical model of MS and how it has been leveraged to this point as a clinical tool, as well as offered insight into a recently initiated effort with it that he presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which was held virtually October 13-15, 2021.More information, including the iPad app that is available, can be found here, MStopography.com.Episode Breakdown: 1:15 – Background on the topographical model and its development 6:00 – Current utilization of the model and its insight into the MS disease course thus far 11:10 – The potential for the model to impact clinical care 13:05 – Neurology News Minute 15:15 – Topographical model-informed data in early MS and ECTRIMS presentation recap 21:10 – The need for better and improved tools to measure disease progression 25:00 – The future use of the topographical model of MS and closing thoughts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: ANVS401 Demonstrates Safety, Improves Parkinson Disease Motor Function Gantenerumab Gets Breakthrough Designation for Alzheimer Following Significant Amyloid Reduction NDA Review for FT218 in Narcolepsy Still Ongoing, FDA Announces Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES1. Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: A dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016;3. doi:10.1212/NXI.0000000000000279 2. Laitman BM, Cook K, Fletcher M, Krieger SC. The topographical model of MS: Empirical evaluation of the recapitulation hypothesis. Mult Scler J Exper Transl Clin. 2018;4(4). doi:10.1177/2055217318806527

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Gregory W. Albers, MD, director, Stanford Stroke Center, Coyote Foundation Professor of Neurology and Neurological Sciences, Stanford Medical Center; and founder, RapidAI. He shared his insight into the development and clinical use of RapidAI, a platform that leverages artificial intelligence to create enhanced, high-quality images from noncontrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion data, aiming to expedient diagnoses, treatment, and transfer decisions Episode Breakdown: 1:15 – Background on RapidAI and its development 3:30 – Findings from the pivotal DIFFUSE clinical program of the system 9:15 – Immediate future plans for RapidAI's capabilities and use 15:55 – Neurology News Minute 18:50 – RapidAI as a complement to the physician in diagnosis 22:00 – Integrating the RapidAI system across the United States 24:50 – The future use of AI in stroke and neuroimaging 28:00 – Closing thoughts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Lecanemab Rolling Submission for Alzheimer Disease Initiated by Eisai, Biogen Fenfluramine sNDA Submitted for Lennox-Gastaut Syndrome Atogepant Approved for Episodic Migraine Prevention Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Patricia Bobryk, MHS, PT, MSCS, ATP, physical therapist, UC Health, and cochair, International Organization of MS Rehabilitation Therapists (IOMSRT). Bobryk shared her insight into the clinical care of MS from the perspective of a rehabilitative specialist, and the importance of including physical therapy approaches as part of the multidisciplinary approach to care as early as possible to ensure more beneficial long-term outcomes for patients, also speaking to the latest advances and developments in rehabilitative medicine.Episode Breakdown: 1:55 – Early intervention with rehab therapy 4:00 – The standard care process for rehab in MS 5:55 – The need for more rehabilitation medicine training for MS 8:20 – Underutilized aspects of rehabilitation therapy in comprehensive care 10:20 – Neurology News Minute 14:05 – Patient-reported outcomes and patient priorities in care 15:40 – The comprehensive care model’s effect on rehabilitation efforts 19:00 – Patient education about rehabilitative care 21:45 – Neurologists’ awareness about the importance of physical therapy 23:50 – Tips for neurologists and MS specialists to get patients this care 26:25 – Recent advances in rehabilitative medicine 29:35 – Closing thoughts on the state of care The stories featured in this week's Neurology News Minute are further detailed here: Noncontact Boxing Exercise Assessed for Parkinson Disease Benefit Opicapone Demonstrates Small Benefit for Sleep in Parkinson Disease Amylyx Announces Plans to Submit NDA for AMX0035 for ALS Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Deena Kuruvilla, MD, director, Westport Headache Institute, who spoke to the current state of affairs in the clinical care of migraine. She also shared her insight into the issues that specialists need to overcome, such as access to therapy, the real-world use of novel treatments for headache disorders, and the advances that are currently in the research and development stage. Episode Breakdown: 1:25 – Trends in the clinical care of migraine over the last year 5:00 –The effect of the COVID-19 pandemic on patients with migraine 7:05 – Ongoing barriers of access to migraine treatments 9:20 – Neurology News Minute 13:25 –Addressing the need for more migraine specialists 15:55 –Real-world use of available migraine therapies and devices 17:20 – Recent introductions to the physician's migraine toolkit 20:40 – Lingering therapeutic needs in migraine and the role of advocacy in improving care The stories featured in this week's Neurology News Minute are further detailed here: FDA Approves Vivistim VNS System for Ischemic Stroke Motor Deficits FDA Approves Brivaracetam for Partial-Onset Seizures in Pediatric Epilepsy Acute Migraine Treatment INP104 Approved Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Adolfo Ramirez-Zamora, MD, associate professor, program director, and chief, Division of Movement Disorders, University of Florida. He detailed the current state of care for patients with advanced Parkinson disease, the ongoing clinical development of therapies, remaining challenges to address in the clinic, and where the field is headed.Episode Breakdown: 2:00 – Overview of the state of care for Parkinson disease 6:00 –The use and importance of patient-reported outcomes 9:20 – Recent advances in the clinical care and research 11:20 – Neurology News Minute 14:10 –The classification of Parkinson disease as a syndrome 15:40 –Ongoing clinical development and biomarker research 20:10 – Improving the education about Parkinson disease The stories featured in this week's Neurology News Minute are further detailed here: FDA Approves Xywav for Idiopathic Hypersomnia AASM Guideline Updates Recommendations for Central Disorders of Hypersomnolence Ravulizumab Phase 3 Trial in ALS Discontinued Due to Lack of Efficacy Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Mitchell S.V. Elkind, MD, MS, MPhil, president, American Heart Association/American Stroke Association (AHA/ASA), and chief, division of neurology clinical outcomes research and population sciences, Columbia University. He discussed the AHA/ASA's recent scientific statement outlining the role of primary care physicians in the poststroke phase of care, as well as the recently updated secondary stroke prevention guidelines.The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Expanded Data From FIREFISH Published, Risdiplam Continues to Improve SMA Outcomes FDA Accepts Resubmission of Diazepam Buccal Film NDA for Seizure Clusters Dosing of WVE-004 Treatment Begins In Frontotemporal Dementia and ALS Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCES 1. Kernan WN, Viera AJ, Billinger SA, et al. Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. Published online July 15, 2021. doi: 10.1161/STR.0000000000000382.2. Kleindorfer DA, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke. Published online May 24, 2021 doi: 0.1161/STR.0000000000000375

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jessica Zwerling, MD, MS, director of the Montefiore Hudson Valley Center of Excellence for Alzheimer's Disease, to find out more about the role that telehealth may play in the future care of Alzheimer and dementia. She shared her experience with it in the last year and offered insight into how it can affect access and impact social determinants of health. The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: NeurologyLive's coverage of the 2021 Alzheimer's Association International Conference Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Raman Malhotra, MD, associate professor of neurology, Washington University in St. Louis, and president, American Academy of Sleep Medicine (AASM). He discussed the AASM's recent position statement calling for a greater emphasis on sleep health in education, clinical practice, inpatient and long-term care, public health promotion, and the workplace due to sleep's critical role in overall health. He also shared insight into the impact the COVID-19 pandemic has had on sleep and the Healthy People 2030 initiative that the AASM is taking part in. This episode also features a new segment, the Neurology News Minute, which will give you quick updates on the following developments in neurology: NIH Awards Funding to Study RNS System in Lennox-Gastaut Syndrome FDA Commissioner Calls for Independent Review of Agency Interactions on Aducanumab Novel SUDEP-3 Inventory Shows Potential to Predict SUDEP Risk Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCERamar K, Malhotra RK, Carden KA, et al. Sleep is essential to health: an American Academy of Sleep Medicine position statement. Published online June 21, 2021. doi: 10.5664/jcsm.9476

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Scott D. Newsome, DO, president, Consortium of Multiple Sclerosis Centers (CMSC), director, Neurosciences Consultation and Infusion Center at Green Spring Station, and associate professor of neurology, Johns Hopkins Medicine; and David Li, MD, FRCPC, professor of radiology, associate member in neurology, and director, Multiple Sclerosis/MRI Research Group, University of British Columbia. The pair spoke about the recent consensus guidelines that were published and developed by the Magnetic Resonance Imaging in Multiple Sclerosis study group; the CMSC working group; and the North America Imaging in Multiple Sclerosis MRI Guidelines working group, in partnership, that marked a massive undertaking in the field of MS care. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. To learn more about the process behind developing these international guidelines, watch our NeurologyLive Peer Exchange: “Updates to the MRI Protocol and Clinical Guidelines for MS: CMSC Working Group.” REFERENCE Wattjes MP, Ciccarelli O, Reich DS, et al; on behalf of the Magnetic Resonance Imaging in Multiple Sclerosis study group, the Consortium of Multiple Sclerosis Centers, and North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. Published online June 14, 2021. doi: 10.1016/S1474-4422(21)00095-8

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with Michael J. Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine. He shared his takeaways from the recent SLEEP 2021 meeting, his perspective on the investigational narcolepsy agent FT218, the current pipeline for excessive daytime sleepiness and cataplexy, the pandemic’s impact on sleep care.Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with a number of people in the Alzheimer disease field with varying and nuanced opinions on this decision to better understand not only what this approval means for the clinical care of patients, but what the downstream effects of it may be. Those individuals, in order of appearance, are: Marwan Sabbagh, MD, director, Cleveland Clinic Lou Ruvo Center for Brain Health, and investigator in the aducanumab trials Anton P. Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program, University of Rochester School of Medicine and Dentistry, and investigator in the aducanumab trials David Knopman, MD, professor of neurology, Mayo Clinic, and investigator in the aducanumab trials Lon Schneider, MD, MS, professor of Psychiatry and the Behavioral Sciences, and Della Martin Chair in Psychiatry and Neuroscience, University of Southern California Keck School of Medicine Robert Howard, MD, MRCPsych, Professor of Old Age Psychiatry, Faculty of Brain Sciences, University College London Ian Kremer, JD, executive director, LEAD Coalition Douglas Scharre, MD, neurologist and director, Division of Cognitive Neurology, Ohio State Wexner Medical Center Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. For more insight and NeurologyLive coverage of aducanumab, click here.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Barry Hendin, MD, clinical professor, University of Arizona; director, Multiple Sclerosis Clinic, Banner University Medical Center; and chief medical officer, Multiple Sclerosis Association of America. He shared his perspective on the recent World MS Day on May 30, the impact awareness efforts have had on care, and how treatment has evolved during his time as an MS physician. Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.